GLP-1 Drugs Like Ozempic and Semaglutide: New Risks for Bone Loss and Tendon Rupture Revealed at AAOS 2026

Key Takeaways

What the Studies Found

Recent research presented at the American Academy of Orthopaedic Surgeons (AAOS) 2026 Annual Meeting in New Orleans has shed light on potential musculoskeletal side effects of GLP-1 receptor agonists — medications like semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro, Zepbound).

Study 1: Bone Health (Michigan State University)

The first study, led by Muaaz Wajahath and colleagues at Michigan State University, examined over 146,000 adults with Type 2 diabetes and obesity (BMI ≥30 kg/m²). Using a large electronic medical records database, researchers compared 73,483 patients on GLP-1 drugs to a matched control group not using them. Over five years, GLP-1 users showed:

These associations held even after adjusting for age, sex, BMI, and comorbidities.

Study 2: Tendon Integrity (University of Texas Medical Branch)

The second study, conducted by Jad Lawand and team at the University of Texas Medical Branch (UTMB), focused on tendon integrity. Analyzing 78,590 matched pairs of obese patients, researchers found a roughly 50% increased relative risk of major tendon ruptures. Specifically:

Perhaps most concerning: many ruptures occurred during low-load activities — simply reaching forward or lifting light objects. These are not typical gym injuries. This qualitative shift raises concerns about how GLP-1 drugs might alter tendon strength or repair mechanisms.

Both studies were podium presentations at AAOS 2026, highlighting their significance to orthopedic specialists. Press coverage has been widespread, with outlets including Medscape, NBC News, and The Washington Post.

Why This Matters for GLP-1 Patients

GLP-1 medications have transformed lives, helping millions achieve weight loss that was previously impossible. But as these studies show, rapid adoption — over 15 million Americans on GLP-1s by 2026 — means we're only now uncovering potential long-term effects.

For patients, these risks are relevant if you have obesity, diabetes, or a history of joint issues. The mechanisms likely involve:

Importantly, these risks are relative, not absolute. In the Michigan State study, absolute osteoporosis rates remained low (4.1%). Most users won't experience these issues. But for the millions on GLP-1 therapy, awareness is the first step toward prevention.

What Patients Can Do

You don't have to stop your GLP-1 therapy. These studies empower you to take proactive steps:

Get screened with DEXA scans. Dual-energy X-ray absorptiometry (DEXA) measures bone density and body composition. If you're on GLP-1s long-term, get a baseline scan and annual follow-ups — especially if you're over 50 or have risk factors.

Prioritize MSK monitoring. Regular check-ins with an orthopedic specialist can track joint and tendon health. Watch for unexplained pain, swelling, or weakness — early intervention prevents catastrophic injuries.

Incorporate strength training. Weight-bearing exercise (resistance training, walking, yoga) is the strongest stimulus for maintaining bone density and tendon strength. Aim for 150+ minutes weekly, including dedicated resistance sessions 3+ times per week.

Optimize nutrition and supplements. Combat potential nutrient gaps with adequate protein (0.7-1.0g per pound of body weight), calcium (1,000-1,200mg daily), vitamin D3+K2 (2,000-5,000 IU daily, guided by blood levels), creatine, and collagen. Your reduced appetite on GLP-1s makes supplementation more important, not less.

Adjust activity awareness. The tendon rupture data suggests caution with sudden, uncontrolled movements — especially reaching, lifting, and twisting. This doesn't mean avoiding activity; it means warming up properly and building tendon resilience through progressive loading.

How MetaOrtho Helps

At MetaOrtho, we specialize in exactly this gap. Our physician-led telehealth platform provides DEXA scan coordination, comprehensive lab monitoring, personalized strength protocols, and ongoing musculoskeletal surveillance — all from home, supervised by a board-certified orthopedic surgeon.

The question isn't whether to take GLP-1 medications. The question is: who is watching your bones, muscles, and tendons while you lose weight?

References